• Amgen Inc., of Thousand Oaks, Calif., declared a 47 cents per-share dividend for the fourth quarter of 2013, which will be paid on Dec. 6, to all stockholders of record as of the close of business on Nov. 14. Read More
DUBLIN – The University of Limerick (UL) has secured €26.3 million (US$36 million) in philanthropic funding from the Atlantic Philanthropies to anchor a €52 million plan to bolster its research capabilities in pharmaceutical science, biomedical engineering and energy research. Read More
SHANGHAI – A cash injection will help an innovative Singapore drug developer to push forward its gastric cancer drug while strengthening its pipeline. Read More
Five months after closing its initial public offering (IPO), Portola Pharmaceuticals Inc. took advantage of the rise in its shares (NASDAQ:PTLA) to price an underwritten public offering of approximately 6.4 million shares of its common stock at $23.75 apiece. Read More
Cancer immunotherapy gained another stamp of approval with the $23 million in gross proceeds raised by Advaxis Inc., which sold about 5.7 million shares plus warrants to buy about 2.8 million more, at a price of $4 per share and $0.01 per warrant. Read More
The good news is that the government is up and running again and a default on federal bills has been averted for at least another few months. The bad news is that government agencies, including the FDA and National Institutes of Health (NIH), are once again pinned to last year’s sequestered spending levels. Read More
• Shire plc, of Dublin, inked an exclusive distribution and supply agreement for Prasco Laboratories, of Cincinnati, to market an authorized generic version of Fosrenol (lanthanum carbonate) chewable tablets. Read More
